NDA 215168 · Ge Hlthcare
Flyrcado
Flurpiridaz F-18 · Intravenous · Radioactive Diagnostic Agent
NovelCDER novel approval, Sep 27, 2024: A radioactive diagnostic drug to evaluate for myocardial ischemia and infarction
Last checked: Nov 20, 2026Latest source record: Sep 27, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Sep 27, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
2 Phase 3, 1 recruiting
FAERS reports
1
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 2, 2026.
FLYRCADO is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. ( 1 )
Mechanism: Flurpiridaz F 18 is an analog of the mitochondrial complex 1 (MC-1) inhibitor, pyridaben. Flurpiridaz F 18 is extracted by the myocardium proportional to the blood flow and binds to heart tissue that has biologically active mitochondria. Therefore, radioactivity in viable myocardium is higher than in infarcted tissue.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- FLYRCADO · FLURPIRIDAZ F-18 5-55mCi/ML · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Flurpiridaz F-18" as an intervention, any sponsor and status, largest first.
- A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.Pivotal-lookingCompleted
Lantheus Medical ImagingIndustry
NCT01347710 · 795 participants · Start Jun 2011 · Primary completion Jul 2013
Drug: Flurpiridaz F18; 99mTechnicium (sestamibi or tetrofosmin) · For: Coronary Artery Disease
Sites: Mobile, Alabama; Scottsdale, Arizona; Beverly Hills, California · 81 sites in all
Lantheus Medical ImagingIndustry
NCT00849108 · 176 participants · Start Jan 2009 · Primary completion Jun 2010
Drug: BMS747158 · For: Ischemia
Sites: Fremont, California; La Jolla, California; Los Angeles, California · 24 sites in all
University of PennsylvaniaAcademic, hospital or other
NCT07910097 · 20 participants (planned) · Start Aug 15, 2026 · Primary completion Sep 1, 2028
Drug: Flurpiridaz PET/CT · For: Hyperparathyroidism
Sites: Philadelphia, Pennsylvania
Lantheus Medical ImagingIndustry
NCT00707499 · 13 participants · Start Sep 2007 · Primary completion May 2008
Drug: BMS747158 · For: Healthy
Sites: Los Angeles, California
Lantheus Medical ImagingIndustry
NCT00707538 · 12 participants · Start Jun 2008 · Primary completion Oct 2008
Drug: BMS747158 · For: Healthy Volunteers
Sites: Los Angeles, California; Baltimore, Maryland
- Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPIPivotal-lookingWithdrawn
Lantheus Medical ImagingIndustry
NCT01681524 · 0 participants · Start Nov 2012 · Primary completion Feb 2014
Drug: Flurpiridaz F18 · For: Coronary Artery Disease
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event1
- radioisotope scan abnormal1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease.
Maddahi J, Agostini D, Bateman TM, et al. · J Am Coll Cardiol 2023 · Clinical Trial, Phase III, Multicenter Study
- General Purpose Deep Learning Attenuation Correction Improves Diagnostic Accuracy of SPECT MPI: A Multicenter Study.
Shanbhag AD, Miller RJH, Lemley M, et al. · JACC Cardiovasc Imaging 2025 · Multicenter Study, Clinical Trial, Phase III
- Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease.
Maddahi J, Lazewatsky J, Udelson JE, et al. · J Am Coll Cardiol 2020 · Clinical Trial, Phase III, Multicenter Study
- Dual-Gated Motion-Frozen Cardiac PET with Flurpiridaz F 18.
Slomka PJ, Rubeaux M, Le Meunier L, et al. · J Nucl Med 2015 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.
Berman DS, Maddahi J, Tamarappoo BK, et al. · J Am Coll Cardiol 2013 · Clinical Trial, Phase II, Comparative Study
Sponsor: Ge Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.